Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Refers to a Non-GAAP financial measure within the meaning of National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112"). Refer to information under the heading ...

President Donald Trump announced a 90-day pause on Wednesday for countries hit by higher US tariffs - except China - whose tariffs he raised to 145%. In a dramatic change of policy, Trump said all ...

Deutsche Telekom also intends to use Google’s Vertex AI platform to develop and scale Gemini-based applications. The company expects that enhanced access to computing resources will support efforts to ...

Four basketball players represented the island at the 3x3 Quest Basketball tournament in Guyana last weekend. Yusef Riley, John Lee, Darae Smith and Miami-based Jonathan Lowe travelled to ...

The model, Gemini 2.5 Flash, will soon launch in Vertex AI, Google’s AI development platform. The company says it offers “dynamic and controllable” computing, allowing developers to adjust ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

Google has launched Vertex AI Media Studio, a suite of generative tools for creating full videos using only text prompts. The platform leverages powerful models, such as Imagen 3 for images ...

Google is adding a new open source framework for building agents to its AI and machine learning platform Vertex AI, along with other updates to help deploy and maintain these agents. It unveiled ...

ExxonMobil has resumed exploration work in the Stabroek block offshore Guyana, as the US supermajor has been focusing activity lately on drilling development wells for a series of projects due to ...

Shares of Vertex have rallied, even amid the broader stock market sell-off. The company is diversifying beyond its dominance in cystic fibrosis treatments. Several catalysts in 2025 support a ...